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Implications from plateleteleukocyte aggregates in inflammatory bowel
disease: Current and future statusInflammatory bowel disease, which includes Crohn’s dis-
ease (CD) and ulcerative colitis (UC), is a chronic auto-
immune inflammatory disease. Imbalance caused by immune
responses is the benchmark of these two human bowel dis-
eases, which have been traditionally considered as typical
examples of T-helper type 1 (Th1) and type 2 (Th2) dominant
diseases, respectively.1 However, the initial concept of Th1/
Th2-mediated chronic inflammation must be re-evaluated in
light of the discovery of an interleukin-12-related cytokine
(interleukin-23). Interleukin-23 is known for its involvement
in the establishment of chronic inflammation and in the
development of a T-helper cell subset producing interleukin-17
(Th17).2 This distinct subset of T-helper cells, Th17 cells, has
been shown to be capable of converting into Th1-producing
cells after stimulation. Th17-related cytokines are regarded
as new players in the control of chronic intestinal inflamma-
tion and homeostasis.3 Therefore, Th1/Th2/Th17 cell pop-
ulations are potential targets of pharmacological manipulation
and novel paradigms open up new avenues for the develop-
ment of therapeutic strategies in the treatment of inflammatory
bowel disease.
Inflammation and thrombosis are closely associated pro-
cesses that may play important roles in the pathogenesis of
inflammatory bowel disease and its complications.4 Apart
from playing a pivotal role in the Th1/Th2/Th17 axis of the
CDþ helper cells, platelets also participate in inflammatory
and thrombotic responses. Furthermore, microparticles bud-
ding from cellular elements during inflammation are related to
vascular dysfunction. Previous studies have shown that the
levels of microparticles derived from leukocytes or platelets
are increased in human inflammatory bowel disease, type 2
diabetes mellitus, and rheumatoid arthritis.5e7 Restoration of
glycemic control in patients with type 2 diabetes mellitus has
been reported to be correlated to the reduction in monocyte-
derived microparticles after either gastric bypass or sleeve
gastrectomy.6
Moreover, a recent study also identified the collagen
receptor glycoprotein VI as a key trigger for the generation of
platelet-derived microparticles in human rheumatoid arthritis,
which leads to the release of cytokine from synovial fibro-
blasts via interleukin-1.8 Collectively, all of the emerging
findings highlight the importance of microparticles derived
from endothelium, leukocytes, or platelets in the pathogenesis1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.12.006of human chronic autoimmune inflammatory diseases and
their complications.
In this issue of the Journal of the Chinese Medical Asso-
ciation, Tekelioglu and his colleagues conducted a prospective
study to investigate whether the levels of plateleteleukocyte
aggregates are increased in inflammatory bowel disease
among a Turkish population.9 Using flow cytometric analysis,
they found that the levels of plateleteleukocyte aggregates
were indeed elevated in patients with inflammatory bowel
disease compared with controls, irrespective of disease activ-
ity. This study included four patients with CD and 16 patients
with UC. However, the sample size is relatively small com-
pared with a previous study.5 Other limitations of this study
included controls that were not age- and gender-matched,
medications that affect the patients were not mentioned, and
co-morbidity and complications such as thrombotic events
were not described and correlated. The number of plate-
leteleukocyte aggregates has been found to be higher in
patients with inflammatory bowel disease; however, this is
lowered by thiopurine medication, suggesting that the use of
immunosuppressive agents, and not corticosteroids or amino-
salicylates, is linked with the reduced formation of plate-
leteleukocyte aggregates.5
Result of another earlier study demonstrated that fewer
leukocytes were found in the blood draining the intestine
compared with blood supplying the intestine in CD and UC.4
In addition, the numbers of circulating platelet aggregates in
CD were increased in venous samples than in paired arterial
samples. The evidence reflects migration of the leukocytes
into extravascular tissues and lumens of the inflamed intestine
(such as the lamina propria) in patients with inflammatory
bowel disease. This supports the concept that platelet activity
is stimulated in the mesenteric microcirculation in CD.4
Gut hormones and adipokines are also involved in the
regulation of intestinal homeostasis and inflammation. For
example, serum levels of ghrelin (anti-inflammatory) are
increased, whereas those of leptin (proinflammatory) are
decreased in patients with UC and CD.10 Furthermore,
receptors for ghrelin and leptin are detectable on the surface of
T lymphocytes, B lymphocytes, monocytes, and neutrophils.
Acyl ghrelin has been reported to inhibit leptin-induced
increases in tumor necrosis factor-a, interleukin-1b, and
interleukin-6 from human T lymphocytes.11hinese Medical Association. All rights reserved.
Fig. 1. Schematic diagram showing the interactions between environmental cues, dendritic cells, leukocytes, hormones, platelets, the endothelium, and Th1/Th2/
Th17 cell populations with their related cytokines in the inflammatory bowel disease. Removing the environmental cues and applying nutraceuticals, sairei-to,
curcumin, guggulsterone, as well as anti-TNF-a therapy with infliximab can modulate the inflammatory status and possibly the mesenteric formation of plate-
leteleukocyte aggregates. CARD/NOD ¼ caspase recruitment domain/nucleotide oligomerization domain; IL ¼ interleukin; TGF-b ¼ transforming growth factor
beta; Th ¼ T-helper cells; TL1a ¼ tumor necrosis factor-like ligand; TNF-a ¼ tumor necrosis factor alpha; Treg ¼ T-regulatory cells.
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manipulate acyl ghrelin and leptin concentrations may be
applied to affect the Th1/Th2/Th17 axis in human inflam-
matory bowel disease.12 In addition, plant extracts and
traditional herbs, such as curcumin, guggulsterone, and
sairei-to, have been advocated to treat T-helper cell-polarized
mucosal immune diseases. Others methods to remove the
environmental cues can also be considered, including short-
chain fatty acid, probiotics, and antibiotics (Fig. 1).
Unfortunately, all of these varied treatment avenues still
cannot better elucidate the cause-and-effect relationship
between plateleteleukocyte aggregates and inflammatory
bowel disease.
Because the incidence rate of UC is trending upwards in
Taiwan13 and thrombotic events significantly contribute to the
associated complications,14 a better recognition of the under-
lying immune-mediated mechanism of plateleteleukocyte
aggregates and adequate treatment for inflammatory bowel
disease are warranted to avoid morbidity and mortality. As
administration of infliximab has become the mainstream
therapy of human CD, and even UC (Fig. 1),15 the next step
should be to investigate whether infliximab treatment with and
without azathioprine in patients with CD (or UC) can reduce
plateleteleukocyte aggregates, and to correlate plate-
leteleukocyte aggregates with the disease activity and clinical
thrombotic event.
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